Figure 4.
AMPK in human adipose tissue of NAFLD subjects. AMPK activity as assessed by the quotient of Thr172 phosphorylated to total AMPK was not significantly different in VAT and SCAT of NAFLD and non NAFLD subjects (p > 0.05). This corresponded to αAMPK mRNA expression in both AT depots (data not shown, p = 0.55 for SCAT and p = 0.84 for VAT). Subjects were matched for main confounders, i.e., age and insulin resistance, with comparable gender distribution between groups. NAFLD patients were obese, while non NAFLD controls were categorized to be overweight. AT was sampled during open abdominal surgery after an overnight starvation period in a human study researching the role of AMPK in the liver. AMPK, AMP-activated protein kinase; HOMA-IR, homeostasis model of insulin resistance; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity scoring; SCAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.
